

Substitute for form 1449A/PTO

ATTORNEY'S DKT No.
017751-017

APPLICATION No.
10/022,241

APPLICANT

FILING DATE
December 20, 2001

GROUP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JAN 2 8 1900

RECEIVED

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
BF	T. Painbeni et al, "Internal morphology of poly(D,L-lactide-co-glycolide) BCNU-loaded microspheres. Influence on drug stability," European Journal of Pharmaceutics and Biopharmaceutics, 45, 1998, pages 31-39.
BF	Henry Brem, et al, "Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas," The Lancet, Vol. 345, April 22, 1995, pages 1008-1012.
BF	Jim H. Kou et al, "Bioerosion and biocompatibility of poly(D,L-lactic-co-glycolic acid) implants in brain," Journal of Controlled Release, 43, 1997, pages 123-130.
BF	Henry Brem, et al, "Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumors," European Journal of Pharmaceutics and Biopharmaceutics, 39 (1), 1993, pages 2-7.
BF	Nobuhiko Aoki, M.D., "Reversible Leukoencephalopathy Caused by 5-Fluorouracil Derivatives, Presenting as Akinetia Mutism," Surg. Neurol, 25, 1986, pages 279-282.
BF	Victor A. Levin, M.D., et al, "5-Fluorouracil and 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) Followed by Hydroxyurea, Misonidazole, and Irradiation for Brain Stem Gliomas: A Pilot Study of the Brain Tumor Research Center and the Childrens Cancer Group," Neurosurgery, Vol. 14, No. 6, pages 679-681.
BF	P. Menei, et al, "Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres," Biomaterials, Vol. 14, No. 6, 1993, pages 470-478.
BF	Jason A. Koutcher, M.D., Ph.D., et al, "Radiation Enhancement by Biochemical Modulation and 5-Fluorouracil," Int. J. Radiation Oncology Biol. Phys., Vol. 39, No. 5, 1997, pages 1145-1152.
BF	R. Jalil et al, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties," J. Microencapsulation, Vol. 7, No. 3, 1990, pages 297-325.
BF	M. Boisdon-Cells, et al, "Preparation and Characterization of 5-Fluorouracil-loaded Microparticles as Biodegradable Anticancer Drug Carriers," J. Pharm. Pharmacol., 47, 1995, pages 108-114.
BF	P. Menei, et al, "Fate and biocompatibility of three types of microspheres implanted into the brain," Journal of Biomedical Materials Research, Vol. 28, 1994, pages 1079-1085.
BF	Robert S. Bourke, et al, "Kinetics of Entry and Distribution of 5-Fluorouracil in Cerebrospinal Fluid and Brain following Intravenous Injection in a Primate," Cancer Research, Vol. 33, July 1973, pages 1735-1746.
BF	Malcolm A. Bagshaw, M.D., "Possible Role of Potentiators in Radiation Therapy," Potentiators in Radiation Therapy, Vol. 85, No. 5, May 1961, pages 822-833.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTORNEY's DKT No.
017751-017APPLICATION NO.
10/022,241

APPLICANT

Philippe MENEI et al

FILING DATE

December 20, 2001

GROUP

RECEIVED
TECH CENTER 6000
JAN 28 2002
6000
6000

6C	William R. Shapiro, M.D., et al, "A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma," <i>J. Neurosurg.</i> , Vol. 76, May 1992, pages 772-781.
6C	Teresa Vietti, et al, "Combined Effect of X Radiation and 5-Fluorouracil on Survival of Transplanted Leukemic Cells," <i>Journal of the National Cancer Institute</i> , Vol. 47, No. 4, October 1971, pages 865-870.
6C	Robert Langer, "Polymer implants for drug delivery in the brain," <i>Journal of Controlled Release</i> , Vol. 16, 1991, pages 53-59.
6C	Dwaine F. Emerich, et al, "Injectable Chemotherapeutic Microspheres and Glioma II: Enhanced Survival Following Implantation into Deep Inoperable Tumors," <i>Pharmaceutical Research</i> , Vol. 17, No. 7, 2000, pages 776-781.
6C	JAN 24 2002 D G. Kotsilimbas, M.D., et al, "Evaluation of parenteral 5-FU on experimental brain tumors," <i>Neurology</i> , 16, 1966, pages 916-918.
6C	J.D. Penn, et al, "Chronic Intratumoral Chemotherapy of a Rat Tumor with Cisplatin and Fluorouracil," <i>Appl. Neurophysiol.</i> , 46, 1983, pages 240-244.
6C	William R. Shapiro, M.D., "Studies on the Chemotherapy of Experimental Brain Tumors: Evaluation of 1-(2-Chloro-ethyl)-3-Cyclohexyl-1-Nitrosourea, Vincristine, and 5-Fluorouracil," <i>Journal of the National Cancer Institute</i> , Vol. 26, No. 2, February 1971, pages 359-368.
6C	E. J. Frazza, "A New Absorbable Suture," <i>J. Biomed. Mater. Res. Symposium</i> , Vol. 1, 1971, pages 43-58.
6C	Thomas E. Goffman, et al, "Long-Term Follow-Up on National Cancer Institute Phase I/II Study of Glioblastoma Multiforme Treated With Iododeoxyuridine and Hyperfractionated Irradiation," <i>Journal of Clinical Oncology</i> , Vol. 10, No. 2, February 1992, pages 264-268.
6C	David H. Moore, M.D., et al, "5-Fluorouracil Neurotoxicity," <i>Gynecologic Oncology</i> , 36, 1990, pages 152-154.
6C	Henry Brem, et al, "Polymers to treat brain tumors," <i>Biomaterials</i> , Vol. 11, November 1990, pages 699-701.
6C	A. I. Torres, et al, "Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure," <i>J. Microencapsulation</i> , Vol. 13, No. 1, 1996, pages 41-51.
6C	Massimo A. Gerosa, M.D., et al, "Improved treatment of a brain-tumor model," <i>J. Neurosurg.</i> , 58, 1983, pages 368-373.
6C	G. E. Visscher, et al, "Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules," <i>Journal of Biomedical Materials Research</i> , Vol. 19, 1985, pages 349-365.
6C	Henry Brem, M.D., et al, "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas," <i>J. Neurosurg.</i> , 74, 1991, pages 441-446.

Examiner Signature	Blessing Fabara	Date Considered	6-29-03
-----------------------	-----------------	--------------------	---------



MAR 25 2002

SHEET 1 OF 1

Substitute for form 1449A/PTO

ATTORNEY'S DKT No.
017751-017

APPLICATION NO.
10/022,241

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT

Philippe

Philippe MENET et al.

FILING DA

December 20, 2001

GROUP

1615

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
6F	Rafael J. Tamargo et al, "Drug Deliver to the Central Nervous System: A Review," Neurosurgery Quarterly, Vol. 2, No. 4, pages 259-279, 1992.
AF	Y. Oda et al, "Trial of Anticancer Pellet in Malignant Brain Tumours; 5-FU and Urokinase Embedded in Silastic," Acta Neurochirurgica, Suppl. 28, pages 489-490, 1979.
bF	Albert H. Soloway et al, "Chemotherapy of Brain Tumors. I. Transplanted Murine Ependymoblastomas," Cancer Chemotherapy Reports, No. 36, pages 1-4, March 1964.
Examiner Signature	Rafael J. Tamargo
	Date Considered
	b-29-03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

A rectangular stamp with a double-line border. The text "FEB 13 2002" is at the top, "DISCLOSE" is in the center, and "TRADEMARK OFFICE" is at the bottom. The word "DISCLOSE" is partially obscured by a diagonal line.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

ATTORNEY'S DKT No.
017751-017

APPLICATION NO.
10/022,241

APPLICANT

FILING DATE

FILED DATE

December 20, 2001

GROUP

TECH CENTER

FEB 15 200

U.S. PATENT DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.